Squamous cell head and neck cancers — cancers that develop in the outer layers of tissue in the oral cavity, throat, larynx, and sinonasal cavity — are the sixth most prevalent cancer worldwide. The five-year survival rate for this type of cancer is 40% to 50%, with a worse prognosis for patients with advanced disease.
Greg Glasgow | 
March 21, 2023
Research Head and Neck Cancer Clinical Trials
Over the past decade, human papillomavirus (HPV) has increasingly been identified as a significant cause of certain head and neck cancers – for example, evidence suggests it causes 70% of oropharyngeal cancers in the United States.
Rachel Sauer | March 03, 2023
Community Head and Neck Cancer
On January 2, tennis great Martina Navratilova revealed that she has been diagnosed with two unrelated cancers: stage 1 throat cancer and early-stage breast cancer.
Greg Glasgow | January 04, 2023
Research Patient Care Head and Neck Cancer Clinical Trials Immunotherapy
Jane Hart is a lot of things: extremely proud mom of Shelby, daughter extraordinaire and apple of Jane’s eye. Dog mom to (deservedly spoiled) Maizy, Taco, Winnie, and Walter. Collector of Talavera pottery. Unabashed “Real Housewives of Salt Lake City” fan. A surprising 71, because she looks at least 10 years younger.
Cancer survivor – stage 4 laryngeal cancer that necessitated a tracheostomy and laryngectomy, that forced her to relearn how to breathe and talk.
Rachel Sauer | December 16, 2022
Press Releases Head and Neck Cancer Cancer
A new study from researchers at the University of Colorado Anschutz Medical Campus has identified a less invasive way to treat a subset of head and neck cancers that could potentially change the standard of care for patients.
Kelsea Pieters | November 28, 2022
Head and Neck Cancer Cancer Oncology Immunotherapy
| A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them. |
Laura Kelley | November 16, 2022
Research Head and Neck Cancer Clinical Trials
A crucial challenge in cancer research is figuring out how to make immunotherapies more effective, channeling, and selectively guiding the body’s own immune responses in targeting and killing tumors.
Rachel Sauer | September 21, 2021
Research Honors Head and Neck Cancer Magazine Funding
Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The SPORE was approved by NCI Scientific Program leadership for FY2021 funding; the projected starting date is July 1.
Greg Glasgow | June 07, 2021
Not all cancerous tumors are created equal. Some tumors, known as “hot” tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.
Greg Glasgow | April 22, 2021
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Valerie Gleaton | April 16, 2021
Studies have long reported that Black cancer patients have poorer outcomes than their white counterparts. But two University of Colorado Cancer Center researchers decided to investigate the data further and figure out why. What they found was that the outcome disparity was caused not by biology, but simply by differences in access to health care.
Cancer Center | October 01, 2020
Research Head and Neck Cancer Cancer Clinical Trials
Nearly two thousand people living in Colorado will be diagnosed with head and neck cancer (HNC) in 2020. Generally, a very aggressive disease, head and neck cancer require expert care that is not widely available in community cancer clinics. However, patients that are not well-represented in clinical studies, especially Hispanic patients, are less likely to get care from centers that specialize in the disease, such as the University of Colorado Cancer Center.
Cancer Center | June 29, 2020
Research Faculty Head and Neck Cancer
If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug’s effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies. That’s because tumors from human cancer samples can only grow in mice with suppressed immune systems. Immunotherapies activate the immune system against cancer. And in a mouse model in which the immune system has been suppressed, there is no immune system to activate against cancer.
Garth Sundem | August 23, 2018
Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million.
Garth Sundem | January 26, 2012
Cancer Health
March 20, 2023
An innovative cell squeezing technology showed great promise in a phase I trial against certain head and neck cancers.
Denver 7
March 16, 2023
Swati Patel, MD, MS, discusses younger people being diagnosed with colon cancer at nearly twice the rate than in 1995.
CPR
March 15, 2023
Doctors increasingly see people contracting colon cancer before the recommended screening age of 45.
KKTV
March 14, 2023
Colon cancer is one of the deadliest cancers -- but with early detection is also one of the most survivable. This is why regular screenings are so key.
